Literature DB >> 27113438

Posterior cricoarytenoid muscle electrophysiologic changes are predictive of vocal cord paralysis with recurrent laryngeal nerve compressive injury in a canine model.

Sidharth V Puram1, Harold Chow1, Che-Wei Wu1,2, James T Heaton3, Dipti Kamani1, Gautham Gorti1, Feng Yu Chiang2, Gianlorenzo Dionigi4, Marcin Barczynski5, Rick Schneider6, Henning Dralle6, Kerstin Lorenz6, Gregory W Randolph1,7.   

Abstract

OBJECTIVES/HYPOTHESIS: Injury to the recurrent laryngeal nerve (RLN) is a dreaded complication of endocrine surgery. Intraoperative neural monitoring (IONM) has been increasingly utilized to assess the functional status of the RLN. Although the posterior cricoarytenoid muscle (PCA) is innervated by the RLN as the abductor of the larynx, PCA electromyography (EMG) is infrequently recorded during IONM and PCA activity after RLN compressive injury remains poorly characterized. STUDY
DESIGN: Single-subject prospective animal study.
METHODS: We employed a canine model to identify postcricoid EMG correlates of postoperative vocal cord paralysis (VCP). Postcricoid electrode recordings were obtained before and after compressive RLN injury associated with VCP.
RESULTS: Normative postcricoid recordings revealed mean amplitude of 1288 microvolt (μV) and latency of 8.2 millisecond (ms) with maximum (1 milliamp [mA]) vagal stimulation, and mean amplitude of 1807 μV and latency of 3.5 ms with maximum (1 mA) RLN stimulation. Following injury that was associated with VCP, there was 62.1% decrement in postcricoid EMG amplitude with maximum vagal stimulation and 80% decrement with maximum RLN stimulation. Threshold stimulation of the vagus increased by 23%, and there was a corresponding 42% decrease in amplitude. For RLN stimulation, latency increased by 17.3% following injury, whereas threshold stimulation increased by 61% with 35.5% decrement in EMG amplitude. Thus, if RLN amplitude decreases by ≥ 80%, with absolute amplitude of ≤ 300 μV or less and latency increase of ≥ 10%, RLN injury is likely associated with VCP.
CONCLUSION: Our results predict postoperative VCP based on postcricoid electromyographic IONM and may guide surgical decision making. LEVEL OF EVIDENCE: NA Laryngoscope, 126:2744-2751, 2016.
© 2016 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Recurrent laryngeal nerve; endocrine; injury; monitoring; postcricoid; thyroid surgery

Mesh:

Year:  2016        PMID: 27113438     DOI: 10.1002/lary.25967

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  4 in total

Review 1.  Neuromonitoring in endoscopic and robotic thyroidectomy.

Authors:  Gianlorenzo Dionigi; Hoon Yub Kim; Che-Wei Wu; Matteo Lavazza; Gabriele Materazzi; Celestino Pio Lombardi; Angkoon Anuwong; Ralph P Tufano
Journal:  Updates Surg       Date:  2017-04-24

2.  Asymmetric recurrent laryngeal nerve conduction velocities and dorsal cricoarytenoid muscle electromyographic characteristics in clinically normal horses.

Authors:  Marta Cercone; Caitlin M Hokanson; Emil Olsen; Norm G Ducharme; Lisa M Mitchell; Richard J Piercy; Jon Cheetham
Journal:  Sci Rep       Date:  2019-02-25       Impact factor: 4.379

3.  Development of a Novel Intraoperative Neuromonitoring System Using an Accelerometer Sensor in Thyroid Surgery: A Porcine Model Study.

Authors:  Eui-Suk Sung; Jin-Choon Lee; Sung-Chan Shin; Hyun-Keun Kwon; Han-Seul Na; Da-Hee Park; Seong-Wook Choi; Jung-Hoon Ro; Byung-Joo Lee
Journal:  Clin Exp Otorhinolaryngol       Date:  2019-06-15       Impact factor: 3.372

4.  Training Courses in Laryngeal Nerve Monitoring in Thyroid and Parathyroid Surgery- The INMSG Consensus Statement.

Authors:  Che-Wei Wu; Gregory W Randolph; Marcin Barczyński; Rick Schneider; Feng-Yu Chiang; Tzu-Yen Huang; Amanda Silver Karcioglu; Aleksander Konturek; Francesco Frattini; Frank Weber; Cheng-Hsin Liu; Henning Dralle; Gianlorenzo Dionigi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-18       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.